

■ ELN Frontiers Meeting 2013

From October 11 to 13, the ELN Frontiers Meeting 2013 takes place in Prague, Czech Republic. This year, the focus is on myeloid neoplasms. Abstracts may be submitted until August 31. ▶ [ELN Frontiers Meeting 2013](#)

■ Publications from the Network (selected)

Acute lymphoblastic leukemia

- ▶ Coskun E et al. MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. *Leuk Res.* 2013 Jun;37(6):647-56.
- ▶ Neumann M et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. *Blood.* 2013 Jun 6;121(23):4749-52.
- ▶ Ottmann OG et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. *Leukemia.* 2013 Jun;27(6):1411-3.
- ▶ Pfeifer H et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. *Leukemia.* 2013 Jun;27(6):1254-62.

Acute myeloid leukemia

- ▶ Cross M et al. Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. *Onco Targets Ther.* 2013 Jun 20;6:741-8.
- ▶ Gaidzik VI et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AML5G). *Blood.* 2013 Jun 6;121(23):4769-77.
- ▶ Grossmann V et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. *Br J Haematol.* 2013 Jun;161(5):649-58.
- ▶ Krönke J et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. *Blood.* 2013 Jul 4;122(1):100-8.
- ▶ Lo-Coco F et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med.* 2013 Jul 11;369(2):111-21.
- ▶ Mustjoki S et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. *Leukemia.* 2013 Jul;27(7):1520-6.
- ▶ Park S et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. *Leukemia.* 2013 Jul;27(7):1479-86.
- ▶ Schaich M et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. *J Clin Oncol.* 2013 Jun 10;31(17):2094-102.
- ▶ Schuurhuis GJ et al. Highly effective mobilization of CD34 positive cells as a poor prognostic factor in acute myeloid leukemia. Possible causes and consequences. *Leuk Res.* 2013 Jul;37(7):727-8.

Acute myeloid leukemia/myelodysplastic syndromes

- ▶ Martino R et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. *Bone Marrow*

Transplant. 2013 Jun;48(6):761-70.

- ▶ Platzbecker U et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. *Leukemia*. 2013 Jun;27(6):1403-7.

Chronic myeloid leukemia

- ▶ Apperley JF. TWIST it but don't spin it. *Blood*. 2013 Jul 25;122(4):470-1.
- ▶ Basak GW et al. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. *Bone Marrow Transplant*. 2013 Jun;48(6):837-42.
- ▶ de Lavallade H et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. *Blood*. 2013 Jul 11;122(2):227-38.
- ▶ Efficace F et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. *Leukemia*. 2013 Jul;27(7):1511-9.
- ▶ Giles FJ et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*. 2013 Jun;27(6):1310-5.
- ▶ Kim TD et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. *Leukemia*. 2013 Jun;27(6):1316-21.
- ▶ Russo D et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. *Blood*. 2013 Jun 27;121(26):5138-44.
- ▶ Solari L et al. A novel recurrent AML1-ETO fusion: tight in vivo association with BCR-ABL1. *Leukemia*. 2013 Jun;27(6):1397-400.
- ▶ Van Etten RA et al. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leuk Lymphoma*. 2013 Jun;54(6):1151-8.
- ▶ Wang X et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. *Clin Pharmacol*. 2013 Jun 10;5:85-97.
- ▶ White HE et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. *Clin Chem*. 2013 Jun;59(6):938-48.

Chronic lymphocytic leukemia

- ▶ Foà R et al. A mechanism-driven treatment for chronic lymphocytic leukemia? *N Engl J Med*. 2013 Jul 4;369(1):85-7.
- ▶ Jebaraj BM et al. BRAF mutations in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2013 Jun;54(6):1177-82.

Myelodysplastic syndromes

- ▶ Itzykson R et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. *J Clin Oncol*. 2013 Jul 1;31(19):2428-36.

Myeloproliferative neoplasms

- ▶ Barosi G et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood*. 2013 Jun 6;121(23):4778-81.
- ▶ Finazzi G et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. *Br J Haematol*. 2013 Jun;161(5):688-94.
- ▶ Harrison CN et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. *Br J Haematol*. 2013 Jul;162(2):229-39.
- ▶ Hernández-Boluda JC et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. *Ann Hematol*. 2013 Jun;92(6):771-5.

- ▶ Merx K et al. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. *Ann Hematol.* 2013 Jul;92(7):907-15.
- ▶ Patterer V et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. *Ann Hematol.* 2013 Jun;92(6):759-69.
- ▶ Ruella M et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. *Exp Hematol.* 2013 Jul;41(7):627-34.

Stem cell transplantation

- ▶ Hicheri Y et al. Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Transpl Infect Dis.* 2013 Jun;15(3):251-8.

Supportive care

- ▶ Engelhard D et al. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. *Transpl Infect Dis.* 2013 Jun;15(3):219-32.

Miscellaneous

- ▶ Dugas M et al. Automated UMLS-Based Comparison of Medical Forms. *PLoS One.* 2013 Jul 4;8(7):e67883.
- ▶ Grossmann V et al. Robustness of amplicon deep sequencing underlines its utility in clinical applications. *J Mol Diagn.* 2013 Jul;15(4):473-84.
- ▶ Heesch S et al. Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. *Ann Hematol.* 2013 Jun;92(6):747-58.
- ▶ Ossenkoppele GJ et al. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. *Br J Haematol.* 2013 Jul;162(2):191-201.
- ▶ Roller A et al. Landmark analysis of DNMT3A mutations in hematological malignancies. *Leukemia.* 2013 Jul;27(7):1573-8.
- ▶ Vianelli N et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. *Haematologica.* 2013 Jun;98(6):875-80.

■ New trials in the ELTR

- CLBH589G2101** A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
- ENESTPath** A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300 mg BID
- ENESTop** A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib
- CLDE225X2203** A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia